Mr. Herrmann joined Novavax in 2010 and is responsible for managing all of Novavax’ legal affairs, including its patent portfolio, transactional and contractual matters, public securities filings, and attending to all the duties of Corporate Secretary. Mr. Herrmann also works with the senior management team at Novavax to define and develop corporate policies and procedures. Prior to joining Novavax, Mr. Herrmann was General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic before it became Ore Pharmaceuticals. Mr. Herrmann worked as Senior Counsel for Celera Genomics and before that was Senior Corporate Counsel at Baxter Healthcare in its Renal Division. Mr. Herrmann holds his Juris Doctorate from the University of Illinois and a Bachelor of Arts degree in Political Science and History from Brown University.

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.